Novartis AG (ADR) (NYSE:NVS) is quickly entering into an engagement with the use of digital technology.
Keep Reading →
February 14 - News, Stock Analysis
Diversity is a hot topic in the US corporate world, and the 10 most diverse companies in the US are showing the way in terms of how a workplace and its management team can be ...
Keep Reading →
February 10 - Lists, News
Did you know five of the 11 largest pharmaceutical companies in the world are US companies? The healthcare and pharmaceutical sector is one of the safest stock market sectors ...
Keep Reading →
January 26 - Lists, News
Novartis AG (ADR) (NYSE:NVS) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will jointly develop Conatus drug emricasan.
Keep Reading →
December 20 - News, Stock Analysis
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that...
Keep Reading →
December 5 - Hedge Funds, News
Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp.
Keep Reading →
November 22 - News, Stock Analysis
Kahn Brothers is a New York-based hedge fund which was founded by famous American businessman Irving Kahn (who recently passed away at the age of 109 as the Oldest Money Manager...
Keep Reading →
November 8 - Hedge Fund Analysis, Hedge Funds, News
Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance.
Keep Reading →
November 2 - News
James Bradner, Novartis AG (NYSE:NVS) Novartis Institutes for BioMedical Research President, has recently confirmed that the company will move the Novartis Institute for Tropical...
Keep Reading →
October 6 - News, Stock Analysis
Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine.
Keep Reading →
September 22 - News, Stock Analysis
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers...
Keep Reading →
August 29 - News, Stock Analysis
Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary progressive multiple...
Keep Reading →
August 26 - News, Stock Analysis
After negotiations with Novartis AG (NYSE:NVS) to lower the price of key leukemia drug Gleevec broke off, the Colombian government is set to take matters into its own hands.
Keep Reading →
June 10 - News, Stock Analysis
We can judge whether Novartis AG (ADR) (NYSE:NVS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Keep Reading →
December 1 - Hedge Funds, News
Most individual investors invest in dividend-paying stocks to benefit from the steady streams of dividend checks, but can also take advantage of stock price appreciation as...
Keep Reading →
November 15 - Dividend Stocks, Hedge Fund Analysis, Hedge Funds, News
The shares of Chiasma Inc (NASDAQ:CHMA) are up by 25% on its first day of trading at $20.02 per share as of the time of writing.
Keep Reading →
July 16 - Hedge Funds, News
When it comes to 11 Biggest Generic Drug Companies in the World one can say that the list hasn’t changed a great deal over the years.
Keep Reading →
June 27 - Lists
James Flynn’s Deerfield Management disclosed an increase in its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) on Friday.
Keep Reading →
December 29 - Hedge Funds, News
Wondering which are the largest pharmaceutical companies in the world? The collective biotech and pharmaceutical industry is known to be one of the most active and wealthy industries...
Keep Reading →
December 20 - Lists
In a discussion with Fox Business News anchors David Asman and Liz Claman from the show ‘After the bell,’ Hank Smith, who is the CIO of Haverford, speaks on his stock picks...
Keep Reading →
July 21 - News
In an interview with Bloomberg, Odile Rundquist, who is an analyst at Helvea, discusses on the second Qtr.
Keep Reading →
July 18 - Earnings Report, News
Rio Tinto plc (ADR) (NYSE:RIO), the world’s second-biggest mining company, is now seeing iron ore trading close to $100 per metric ton.
Keep Reading →
July 17 - News
Innovation is everything when it comes to the pharmaceutical sector.
Keep Reading →
September 23 - News
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Keep Reading →
September 23 - News
More than anything, biotech companies need investors who are true believers in their products.
Keep Reading →
September 17 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
September 17 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News
When most biotech investors think of cancer treatments, they tend to think of large established players like Roche and Amgen.
Keep Reading →
September 12 - News
The ongoing convergence of the tech and health care industries has yielded some remarkable advances in telehealth, electronic health records, or EHRs, and mobile apps.
Keep Reading →
September 12 - News
Johnson & Johnson (NYSE:JNJ) recently announced a recall of around 200,000 bottles of Motrin Infants' Drops Original Berry Flavor.
Keep Reading →
September 11 - News
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News
The Cooper Companies, Inc. (NYSE:COO), or more formally "The Cooper Companies" is a sort of odd duck in the med-tech world.
Keep Reading →
September 10 - News
Earlier this month, I wrote an article explaining that I liked Incyte Corporation (NASDAQ:INCY) on the basis of the blockbuster potential of its only approved drug, Jakafi...
Keep Reading →
September 6 - News
Pharmaceutical firms spend a lot of money to influence physicians to prescribe their products.
Keep Reading →
September 5 - News
In the financial world, there are many methods market participants can use to track the equity markets.
Keep Reading →
September 3 - News
Designed as a way to bring potentially life-changing drugs to pharmacy shelves faster than ever, the Food and Drug Administration Safety and Innovation Act, which passed last ...
Keep Reading →
September 3 - News
As an investor in the health care sector, it can sometimes feel like everything -- and everyone -- is out to get you.
Keep Reading →
August 30 - News
In the 21st century investor’s toolkit, there are dozens of methods market participants can use to monitor the equity markets.
Keep Reading →
August 29 - News
The existence of ADHD, or attention deficit hyperactivity disorder, has been a hot-button topic since the 1970s.
Keep Reading →
August 28 - News
Incyte Corporation (NASDAQ:INCY) takes the top spot on our humongous health-care stocks list.
Keep Reading →
August 26 - News
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Keep Reading →
August 26 - News
Curis, Inc. (NASDAQ:CRIS) and Roche Holding Ltd.
Keep Reading →
August 26 - News
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 25 - News
Well, OK, many parts of the Patient Protection and Affordable Care Act, commonly referred to as Obamacare, have already been implemented.
Keep Reading →
August 25 - News
For a subgroup of the patients, the hazard ratio for overall survival in late-stage pancreatic cancer patients taking Incyte Corporation (NASDAQ:INCY)'s Jakafi and Roche's Xeloda...
Keep Reading →
August 23 - News
To the average investor, there are plenty of gauges investors can use to track Mr. Market. Some of the most useful are hedge fund and insider trading interest.
Keep Reading →
August 22 - News
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Keep Reading →
August 22 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
August 21 - News